Loading
A phase 3 trial of Pasritamig, Docetaxel and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT07225946 by Janssen Research & Development, LLC, with 800 participants planned, started 2025-12-19 and due to reach its primary completion in 2027-11-19. Interventions recorded: Pasritamig, Docetaxel and Prednisone/Prednisolone.
Shares Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Prednisone, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Prednisone, Docetaxel, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.